MedTrace Logo

Prolonging Remission in Depressed Elderly (PRIDE)

NCT01028508 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 247

Last updated 2017-04-11

No results posted yet for this study

Summary

This study will determine whether medications alone or medications and electroconvulsive therapy (ECT) work best to prevent depressive relapse and to improve quality of life for older people with severe mood disorders.

Conditions

Interventions

DRUG

lithium and Venlafaxine

Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l

PROCEDURE

ECT

Procedure: ECT RUL ultra brief pulse ECT, 4 treatments in one month and then treatment on an as-needed basis for 5 months Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l

Sponsors & Collaborators

Principal Investigators

  • Charles Kellner, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2015-09-30
Completion
2016-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01028508 on ClinicalTrials.gov